To Teva next and the Israeli Generics Company has established a Global Specialty Medicines Group and has appointed Dr. Rob Koremans to lead it in the capacity of President and CEO.
Koremans, who has been President and CEO of Teva Europe since last year, has had a series of high-end roles at companies including Sanofi, Grunenthal and the Serono Group, said: “Teva’s unique capabilities in Specialty pharmaceuticals are now concentrated in the new GSM group, so we can deliver more effectively on our commitment to our patients and other stakeholders.”
In related news, Dipankar Bhattacharjee, formerly Senior Vice President Western Europe, has been promoted to the position of President and CEO of Generics Europe and Larry Downey, formerly Executive Vice President of Teva US Brands, has been appointed President, North America Specialty Medicines.
And follow the latest development between Teva and Lonza on their biosimilars joint venture here.